Treatment of chronic kidney disease-mineral bone disorder and vascular complications

Therapeutic Apheresis and Dialysis

Volumn 10, Issue SUPPL. 1, 2006, Pages

  Moe, Sharon M ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone; Calcimimetics; Kidney; Renal osteodystrophy; Sevelamer; Vascular calcification

Indexed keywords

ALUMINUM; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; CINACALCET; LANTHANUM; MAGNESIUM; SEVELAMER; VITAMIN D; VITAMIN D DERIVATIVE;

BLOOD VESSEL CALCIFICATION; BONE REMODELING; CALCIUM METABOLISM; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DIALYSIS; DISEASE CLASSIFICATION; HORMONE INHIBITION; HUMAN; METABOLIC BONE DISEASE; PHOSPHATE BLOOD LEVEL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; TREATMENT OUTCOME;

EID: 33845634353     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2006.00434.x     Document Type: Conference Paper

References (11)

1. Block GA, Klassen P, Danese M. ASN 2003 SA-PO801. ASN 2003 SA-PO801, 2003.
2. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18.
3. Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006 April 26 (epub ahead of print).
4. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52.
5. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-48.
6. Raggi P, James G, Burke SK et al. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. J Bone Miner Res 2005 May;20:764-72. Epub 2004 December 20.
7. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004;15:1943-51.
8. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-56.
9. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516-25.
10. Moe SM, Cunningham J, Adler S et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCI. Nephrol Dial Transplant 2005;20:2186-93.
11. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005;68:1793-800.